Press releases

Month Year

Email alerts

Sep 1, 2022

Medtronic ADAPT study results published in The Lancet Diabetes & Endocrinology show improved glycemic control and treatment satisfaction among those using MiniMed™ 780G system¹, compared to insulin injections

First-of-its-kind study demonstrates individuals using the Medtronic system achieved 1.4% absolute reduction in A1c and 27.6% absolute increase in Time in Range DUBLIN, Sept. 1, 2022 /PRNewswire/...
- Photos 1
Dec 22, 2021

CMS expands diabetes Medicare coverage to include CGMs that integrate with Medtronic insulin pumps

Medicare coverage for Medtronic customers will be available 60 days after official publication

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) will expand Medicare coverage for all types of...
Dec 15, 2021

Medtronic Diabetes receives FDA warning letter

Medtronic plc (NYSE:MDT) today announced it received a warning letter from the U.S. Food and Drug Administration (FDA) on December 9 for the company's Northridge, California, facility, the...
Oct 19, 2021

Children achieve Time in Range mirroring well-controlled adults for the first time in real-world study of the MiniMed™ 780G system

Harder to manage pediatric and adolescent patients achieve 74% Time in Range, and 82% overnight Time in Range, well surpassing clinical consensus guidelines for glycemic control DUBLIN, Oct. 19,...
Jun 28, 2021

Medtronic InPen™ Real-World Data and Extended Infusion Set* Pivotal Trial Results Demonstrate Strong Clinical Outcomes and Positive User Experience

Data Were Presented at the American Diabetes Association 81st Scientific Sessions DUBLIN, June 28, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today...

Show per page

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa